Trials / Completed
CompletedNCT01211145
Zomig - Treatment of Acute Migraine Headache in Adolescents
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,653 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate if Zomig® Nasal Spray will help children (age 12-17 years) with migraine headaches feel better. This will be done by comparing 3 different doses of Zomig Nasal Spray with placebo nasal spray (inactive treatment).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo nasal spray |
| DRUG | Zolmitriptan | 0.5 mg nasal spray |
| DRUG | Zolmitriptan | 2.5 mg nasal spray |
| DRUG | Zolmitriptan | 5.0 mg nasal spray |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2010-09-29
- Last updated
- 2016-05-18
- Results posted
- 2014-10-24
Locations
74 sites across 8 countries: United States, Estonia, Finland, Hungary, Latvia, Poland, Serbia, Slovakia
Source: ClinicalTrials.gov record NCT01211145. Inclusion in this directory is not an endorsement.